HomeInsightsPE

Suven Pharmaceuticals Ltd PE Ratio

Suven Pharmaceuticals Ltd PE Ratio

stocks purchased

₹ 0.3 Cr

Volume Transacted

(Dec 11, 2024)

stocks purchased

2.1 K

Stocks Traded

(Dec 11, 2024)

Last Updated on: Dec 11, 2024

Image

Suven Pharmaceuticals Ltd

NSE: SUVENPHAR

PE

135.8

Last updated on: Dec 11, 2024

Key Highlights

  • The P/E Ratio of Suven Pharmaceuticals Ltd is 135.8 as of 11 Dec 15:30 PM .
  • The P/E Ratio of Suven Pharmaceuticals Ltd changed from 8.1 on March 2020 to 57.3 on March 2024 . This represents a CAGR of 47.89% over 5 years.
  • The Latest Trading Price of Suven Pharmaceuticals Ltd is ₹ 1296 as of 11 Dec 15:30 .
  • The PE Ratio of Pharmaceuticals Industry has changed from 28.2 to 27.1 in 5 years. This represents a CAGR of -0.79%.
  • The PE Ratio of Automobile industry is 20.3. The PE Ratio of Finance industry is 17.8. The PE Ratio of IT - Software industry is 30.5. The PE Ratio of Pharmaceuticals industry is 40.0. The PE Ratio of Retail industry is 157.6. The PE Ratio of Textiles industry is 37.6 in 2024.

Historical P/E Ratio of Suven Pharmaceuticals Ltd

No data available

Company Fundamentals for Suven Pharmaceuticals Ltd

No data available

Image

Suven Pharmaceuticals Ltd

NSE: SUVENPHAR

Share Price

₹ 1296.85

3.00 (0.23%)

stock direction

Last updated on: Dec 11, 2024

Market Price of Suven Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Suven Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
11 Dec 20241296.85
10 Dec 20241293.85
09 Dec 20241307.8
06 Dec 20241305.3
05 Dec 20241295.15
04 Dec 20241299.4
03 Dec 20241290.55
02 Dec 20241307.95
29 Nov 20241303.85
28 Nov 20241274.9

SWOT Analysis Of Suven Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Suven Pharmaceuticals Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Suven Pharmaceuticals Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Suven Pharmaceuticals Ltd13533,013
Sun Pharmaceuticals Industries Ltd384,35,407
Divis Laboratories Ltd851,57,489
Cipla Ltd251,17,443
Torrent Pharmaceuticals Ltd651,14,197
Mankind Pharma Ltd491,05,098

Key Valuation Metric of Suven Pharmaceuticals Ltd

No data available

No data available

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

Historical Market Cap of Suven Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue of Suven Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Suven Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Suven Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Dividend Payout of Suven Pharmaceuticals Ltd

No data available

* All values are in %

About Suven Pharmaceuticals Ltd

  • Suven Pharmaceuticals Limited (SPL) is a bio-pharmaceutical company, incorporated on 6th November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies. The Company is a CDMO that supports global life sciences industry and fine chemical majors in their NCE development endeavors.
  • Its services include custom synthesis, process R&D, scale-up and contract manufacturing of intermediates, APIs and formulations.
  • Suven Pharma Inc., a Delaware Company, is a WOS (wholly owned subsidiary) of SPL, is a SPV (Special Purpose Vehicle) created on 9th March 2019, for undertaking various business opportunities in Pharma Industry.

Suven Pharmaceuticals Ltd News Hub

News

Suven Pharmaceuticals consolidated net profit declines 49.61% in the June 2024 quarter

Net profit of Suven Pharmaceuticals declined 49.61% to Rs 60.77 crore in the quarter ended...

Read more

2024-08-09 00:00:00

News

Suven Pharmaceuticals to hold board meeting

Suven Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 Au...

Read more

2024-08-06 00:00:00

News

Suven Pharmaceuticals appoints Vivek Sharma as new Executive Chairman

Suven Pharmaceuticals announced the appointment of Vivek Sharma as the new Executive Chair...

Read more

2024-09-19 00:00:00

News

Board of Suven Pharmaceuticals approves change in Executive Chairperson

The Board of Suven Pharmaceuticals at its meeting held on 19 September 2024 has taken on r...

Read more

2024-09-19 00:00:00

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for PE of Suven Pharmaceuticals Ltd

What is the current PE Ratio of Suven Pharmaceuticals Ltd?

The Current PE Ratio of Suven Pharmaceuticals Ltd is 135.8 as on 11 Dec 2024.

What is the average PE Ratio of the Pharmaceuticals industry?

The average industry PE Ratio of Pharmaceuticals is 40.0 as on 11 Dec 2024.

What was the PE Ratio of Suven Pharmaceuticals Ltd last year?

The PE Ratio of Suven Pharmaceuticals Ltd was 29.25 last year, now the PE ratio is 135.8, showing a year-on-year growth of 364.3%.

What does the PE Ratio of Suven Pharmaceuticals Ltd indicate about its stock?

The PE Ratio of Suven Pharmaceuticals Ltd is 135.8. This ratio indicates that investors are willing to pay 135.8 times the earnings per share for each share of Suven Pharmaceuticals Ltd.

What is the PE Ratio Growth of Suven Pharmaceuticals Ltd in comparison to its Earnings per Share (EPS) growth rate?

The PE Ratio of Suven Pharmaceuticals Ltd grew by 364.3% whereas, the EPS ratio grew by 35.1.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions